UB Paderborn / Katalog / Suche / in CDI

Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate

PLoS pathogens, 2015-06, Vol.11 (6), p.e1004995-e1004995

2015

Link zum Volltext

Verfügbarkeit prüfen

Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)

PloS one, 2020-12, Vol.15 (12), p.e0240338

2020

Link zum Volltext

Verfügbarkeit prüfen

Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models

International journal of molecular sciences, 2023-11, Vol.24 (22), p.16274

2023

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4432-4441

2008

Link zum Volltext

Verfügbarkeit prüfen

Activation Pathway of a Nucleoside Analog Inhibiting Respiratory Syncytial Virus Polymerase

ACS chemical biology, 2017-01, Vol.12 (1), p.83-91

2017

Link zum Volltext

Verfügbarkeit prüfen

1382 Discovery of ALG-094103, a liver-targeted and orally bioavailable small molecule PD-L1 inhibitor for the treatment of liver cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1537-A1537

2023

Link zum Volltext

Verfügbarkeit prüfen

1381 Discovery of ALG-093989, a highly potent and orally bioavailable small molecule PD-L1 inhibitor for the treatment of cancers

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1536-A1536

2023

Link zum Volltext

Verfügbarkeit prüfen

Development of a Hyperglycosylated IFN Alfacon-1 (CIFN): Toward Bimonthly or Monthly Dosing for Antiviral Therapies

Journal of interferon & cytokine research, 2015-08, Vol.35 (8), p.621

2015

Link zum Volltext

Verfügbarkeit prüfen

Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs

Bioorganic & medicinal chemistry, 2007-08, Vol.15 (16), p.5519-5528

2007

Link zum Volltext

Verfügbarkeit prüfen

HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives

Bioorganic & medicinal chemistry letters, 2009-08, Vol.19 (15), p.4476-4479

2009

Link zum Volltext

Verfügbarkeit prüfen

Gatekeepers in the Ribosomal Protein S6: Thermodynamics, Kinetics, and Folding Pathways Revealed by a Minimalist Protein Model

Journal of molecular biology, 2004-07, Vol.340 (3), p.571-585

2004

Link zum Volltext

Verfügbarkeit prüfen

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

Biochemical and biophysical research communications, 2021-05, Vol.555, p.134-139

2021

Link zum Volltext

Verfügbarkeit prüfen

Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models

Journal of hepatology, 2023-06, Vol.78, p.S1030-S1031

2023

Link zum Volltext

Verfügbarkeit prüfen

FRI-241 - Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models

Journal of hepatology, 2023-06, Vol.78, p.S1030-S1031

2023

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′‑C‑methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection

Journal of medicinal chemistry, 2019-05, Vol.62 (9), p.4555-4570

2019

Link zum Volltext

Verfügbarkeit prüfen

Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B

Journal of hepatology, 2022-07, Vol.77, p.S853

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1758: Discovery of novel potent and selective inhibitors of PRMT5 with anti-tumor activity in hepatocellular carcinoma and lung pre-clinical models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1758-1758

2020

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C

Journal of medicinal chemistry, 2020-09, Vol.63 (18), p.10380-10395

2020

Link zum Volltext

Verfügbarkeit prüfen

Regulation of gene transcription by thyroid hormone receptor [beta] agonists in clinical development for the treatment of non-alcoholic steatohepatitis

PloS one, 2020-12, Vol.15 (12), p.e0240338

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4520: Preclinical characterization of ALG-031048, a novel STING agonist with potent anti-tumor activity in mice

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4520-4520

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular, cellular, and pharmacological characterization of beta-selective partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis

Journal of hepatology, 2020-08, Vol.73, p.S448-S449

2020

Link zum Volltext

Verfügbarkeit prüfen

FRI100 - Molecular, cellular, and pharmacological characterization of beta-selective partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis

Journal of hepatology, 2020-08, Vol.73, p.S448-S449

2020

Link zum Volltext

Verfügbarkeit prüfen

Stripe melting in a two-dimensional system with competing interactions

Physical review letters, 2000-05, Vol.84 (20), p.4657-4660

2000

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)

Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

Activation Pathway of a Nucleoside Analog Inhibiting Respiratory Syncytial Virus Polymerase

1382 Discovery of ALG-094103, a liver-targeted and orally bioavailable small molecule PD-L1 inhibitor for the treatment of liver cancer

1381 Discovery of ALG-093989, a highly potent and orally bioavailable small molecule PD-L1 inhibitor for the treatment of cancers

Development of a Hyperglycosylated IFN Alfacon-1 (CIFN): Toward Bimonthly or Monthly Dosing for Antiviral Therapies

Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs

HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives

Gatekeepers in the Ribosomal Protein S6: Thermodynamics, Kinetics, and Folding Pathways Revealed by a Minimalist Protein Model

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models

FRI-241 - Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models

Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′‑C‑methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection

Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B

Abstract 1758: Discovery of novel potent and selective inhibitors of PRMT5 with anti-tumor activity in hepatocellular carcinoma and lung pre-clinical models

Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C

Regulation of gene transcription by thyroid hormone receptor [beta] agonists in clinical development for the treatment of non-alcoholic steatohepatitis

Abstract 4520: Preclinical characterization of ALG-031048, a novel STING agonist with potent anti-tumor activity in mice

Molecular, cellular, and pharmacological characterization of beta-selective partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis

FRI100 - Molecular, cellular, and pharmacological characterization of beta-selective partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis

Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate: e1004995

Stripe melting in a two-dimensional system with competing interactions

Suchergebnisse filtern